MAP2K2 Gene Alteration
1 clinical trials · Condition
◉ Watch MAP2K2 Gene Alteration
| Record | Firm | Date |
|---|---|---|
| Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations (NCT04488003) | BioMed Valley Discoveries, Inc | 2021-01-07 |
Track MAP2K2 Gene Alteration automatically
Every clearance here is in the API, with alerts when new ones post.